AstraZeneca’s Tagrisso has taken the EGFR lung cancer market by storm, but some patients develop resistance to the therapy. Enter Chi-Med and its MET inhibitor, savolitinib. More: Chi-Med, AstraZeneca's savolitinib helps some Tagrisso-resistant EGFR lung cancer patients Source: fierce
read moreBristol-Myers Squibb has found success with its Opdivo-Yervoy combo in treating various common tumors. But it turns out the duo can help some patients with rare tumors, too. More: Bristol-Myers Squibb's Opdivo-Yervoy duo provokes response in rare tumors Source: fierce
read moreWhen it comes to Bristol-Myers Squibb’s Celgene buyout, two influential proxy advisory firms have spoken—and they’re in favor of the mammoth tie-up. That support deals a blow to investor rebels fighting the merger. More: BMS-Celgene merger chances improve with backing
read moreOnly a month after making some senior-level changes, Daiichi Sankyo now figures it’s the right time to change its CEO as well. The company’s current president will take the helm and steer the company’s transition toward oncology, a move evident
read moreJohnson & Johnson’s anticoagulant Xarelto has picked up an industry first. On Friday, it became the subject of the first-ever TV drug ad with a list price included. More: Price checked: J&J launches industry-first TV ad with drug list price Source:
read moreNovo Nordisk this last week reached an agreement that will hold generic competition to its newer diabetes drugs for another five years. With that in the bag, it can now focus on next-generation products and so is investing nearly $100
read more© 1994 - 2024 B.M. Pharmaceuticals